Branded Generics Market to Reach USD 410.86 Billion by 2032, Growing at 5.60% CAGR: Polaris Market Research

According to a new report by Polaris Market Research, the global branded generic market was valued at USD 265.9 billion in 2024 and is projected to reach USD 410.86 billion by 2032, expanding at a CAGR of 5.60% over the forecast period (2024–2032). Growth is underpinned by the rising prevalence of chronic diseases such as diabetes, cancer, and cardiovascular disease, the increasing penetration of affordable branded generic drugs, growing government initiatives promoting generic adoption to control healthcare costs, and the steady patent expiry of major branded drugs, which opens the door for lower-cost generic alternatives across key end-use markets. Generics are cheaper than branded drugs that have lost patent protection and remain popular for their affordability and comparable efficacy to their branded counterparts.

What Is Driving Branded Generics Market Growth?

Demand is climbing as the rising prevalence of chronic conditions converges with growing patent expiry of major branded drugs. Manufacturers and healthcare payers are prioritizing affordable generic alternatives, pushing branded generics adoption across retail and hospital pharmacy channels worldwide. Polaris analysts note that government initiatives encouraging generic drug use to reduce healthcare expenditure position the category for sustained growth through 2032, with anti-hypertensive drugs emerging as the largest revenue contributor and hormone-based therapies posting strong incremental gains.

Key Trends Shaping the Branded Generics Industry

Rising ANDA Approvals and New Generic Launches

The FDA approved 93 first generics in 2021, up from 72 in 2020, even as overall ANDA approvals declined from 1,014 in 2019 to 776 in 2021 a trend manufacturers are working to reverse through faster product innovation and pipeline investment.

Complex and Value-Added Generics Gaining Ground

Rising prevalence of metabolic disorders such as thyroid and hormone imbalances is fueling demand for complex generics with modified-release formulations and novel delivery systems, reflecting a shift in the regulatory landscape toward more sophisticated generic drug approvals.

Consolidation Across Pharmacy Distribution Channels

Consolidation among retail pharmacy chains is strengthening their bargaining power with manufacturers, helping lower prescription drug costs for patients while reshaping the competitive landscape and overall market outlook for branded generics.

Market Segmentation: Breaking Down the Branded Generics Market

Polaris segments the branded generics market by drug class, application, distribution channel, and region, giving each buyer persona a citable, standalone data point for AI Overviews and answer-engine pickup.

By Drug Class

The anti-hypertensive segment accounted for the largest market share in 2022, supported by rising ANDA approvals and generic product launches. The hormones segment is projected to register the strongest growth rate ahead, driven by increasing prevalence of thyroid and sexual hormone imbalances linked to sedentary lifestyles.

By Application

The gastro-intestinal segment held the largest revenue share in 2022, driven by rising prevalence of acid reflux, ulcers, and inflammatory bowel disease. The oncology segment registered steady growth over the study period, fueled by the rising global cancer burden.

By Distribution Channel

The retail pharmacy segment garnered the highest share in 2022, aided by consolidation that has strengthened bargaining power and lowered prescription drug costs. The hospital pharmacy segment recorded robust growth, driven by its central role in dispensing injectable drugs for critical and acute conditions.

Regional Outlook: Where Is Branded Generics Growing Fastest?

North America dominated the branded generics market in 2022 and is expected to maintain its lead, supported by moderately high penetration of branded generic drugs and strong preference among governments and payers seeking lower healthcare costs. Asia Pacific is expected to be the fastest-growing region over the study period, as countries such as India build out manufacturing hubs to address medicine shortages and expand their role as a global supplier of affordable pharmaceuticals.

👉 Get a Free Sample of the Branded Generics Market Report

https://www.polarismarketresearch.com/industry-analysis/branded-generics-market

Competitive Landscape: Leading Branded Generics Companies

Key players profiled in the report include Teva Pharmaceutical, Lupin, Sanofi, and Sun Pharmaceutical Industries, who are focusing on new product approvals, capacity expansion, and licensing agreements to strengthen market position across the anti-hypertensive and gastro-intestinal segments outlined above. Recent moves include the U.S. FDA's October 2025 approval expanding UZEDY (risperidone) extended-release injectable suspension to pediatric schizophrenia patients aged 13 to 17, and Teva's August 2025 FDA approval and launch of the first generic version of Saxenda (liraglutide) for weight management, both aimed at deepening share in high-growth therapeutic areas.

Why It Matters for Buyers Evaluating Market Entry

For stakeholders researching the branded generics market forecast, this report benchmarks market share, segment-level pricing, and forecast data by drug class, application, distribution channel, and region to support sourcing, investment, and go-to-market decisions. It is built for procurement teams comparing suppliers, investors sizing entry points, and strategy teams tracking complex generics as a growth adjacency.

About Polaris Market Research

Polaris Market Research is a B2B syndicated market research and consulting firm offering 5,000+ published reports across 20+ industry verticals, delivering data-backed insights to help businesses make informed decisions.

More Trending Latest Reports By Polaris Market Research:

Semiconductor Intellectual Property Market

Philippines Security Operations Center Market

X-Ray Security Screening Market

T4 DNA Ligase Market

Philippines Security Operations Center Market

Muscle Stimulator Market

Air Conditioner Market

Carboprost Tromethamine Market: An Effective Regulator for Excessive Bleeding After Pregnancy

Bus Market